Cardiovascular changes after naloxone administration in propofol-sedated piglets during opioid overdose.
BACKGROUND
Naloxone is an opioid receptor antagonist. Even when used in modest doses, it has been associated with serious cardiopulmonary side-effects. In this experimental porcine study, we examined the cardiac effects of naloxone during an opioid overdose.


METHODS
Cardiac parameters, changes in the left ventricular compliance and the magnitude of catecholamine release were evaluated in eight spontaneously breathing piglets under propofol sedation. Cardiac parameters were recorded every 30 s and transthoracic echocardiography was used for the continuous assessment of cardiac performance. Respiratory arrest was induced by morphine (8 mg/kg). Ten minutes after morphine administration, naloxone (80 microg/kg) was injected intravenously. Every 5 min, arterial blood gases were measured and, every 10 min, a sample for the analysis of plasma catecholamines was drawn.


RESULTS
There were no statistically significant changes in left ventricular ejection fraction and no signs of pulmonary hypertension. There was a statistically significant increase in the mean arterial pressure immediately after naloxone administration and in norepinephrine concentration before naloxone administration. After naloxone administration, the plasma catecholamine levels decreased in all but one animal. Two animals developed cardiac arrest (pulseless electrical activity and ventricular fibrillation) shortly after receiving naloxone. Although they were both administered naloxone prematurely due to hypoxic bradycardia, naloxone could have contributed to the development of ventricular fibrillation.


CONCLUSIONS
Naloxone did not cause changes in ejection fraction or mean pulmonary artery pressure in hypoxic and hypercarbic conditions. After naloxone administration, the plasma catecholamine levels returned to baseline in all but one animal, and two animals developed cardiac arrest.
Boyd
J J
JJ
Helsinki Emergency Medical Service, Helsinki University Central Hospital, Helsinki, Finland. james.boyd@hus.fi
Kyttä
J V
JV
Aittomäki
J V
JV
Rosenberg
P H
PH
Seppälä
T A
TA
Randell
T T
TT
D000701:Analgesics, Opioid / Q000633:toxicity*; D000818:Animals; D002245:Carbon Dioxide / Q000097:blood; D002320:Cardiovascular Physiological Phenomena / Q000187:drug effects*; D002395:Catecholamines / Q000097:blood; D004195:Disease Models, Animal; D062787:Drug Overdose; D004562:Electrocardiography / Q000187:drug effects; D006863:Hydrogen-Ion Concentration; D009270:Naloxone / Q000494:pharmacology*; D010313:Partial Pressure; D015742:Propofol / Q000494:pharmacology*; D013552:Swine
D000701:Analgesics, Opioid; D002395:Catecholamines; D002245:Carbon Dioxide; D009270:Naloxone; D015742:Propofol